DG DISPATCH - WCO: Fosamax Effective For Men With Osteoporosis
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




DG DISPATCH - WCO: Fosamax Effective For Men With Osteoporosis

By W. A. Thomasson, PhD
Special to DG News

CHICAGO, IL -- June 19, 2000 -- There is no drug approved currently for the treatment of osteoporosis in men.

Rene Rizzoli, MD, of University Hospital in Geneva, Switzerland, told journalists covering the World Congress on Osteoporosis that this is about to change.

Data presented Saturday (June 17) by Dr. Rizzoli and his colleagues show that Fosamax (alendronate sodium) reduces vertebral fracture in men as it does in women.

The study, which was described as the first large, randomized, multi-center study ever conducted on male osteoporosis, enrolled 241 osteoporotic men aged 31 to 87 years. Half of these men already had vertebral fractures when the study began.

Ninety-five subjects were randomized to receive placebo and 146 received Fosamax at a dose of 10 milligrams/day for two years.

Over the course of the two-year follow-up, men receiving placebo experienced 5.3 non-vertebral fractures and 7.1 vertebral fractures. Fosamax-treated men experienced 4.1 non-vertebral fractures and 0.8 vertebral fractures. The difference in vertebral fractures is statistically significant (p = 0.017).

The drug also eliminated the height loss that typically accompanies vertebral fracture. In addition, Fosamax-treated men also saw bone mineral density increases far greater than those seen in the control group (p < 0.001).

Fosamax was also stated to be well tolerated, with similar rates of adverse events, including those in the upper gastrointestinal tract, between placebo and active-drug groups.

"We have now a drug which is able to decrease the incidence of vertebral fracture in men with osteoporosis," Dr. Rizzoli concluded.

Related Link: Fosamax (alendronate sodium).

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities